Acquired hemophilia A (AHA) is an autoimmune disease caused by an autoantibody to
factor VIII. Patients are at risk of severe and fatal hemorrhage until the inhibitor is eradicated …

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII).
Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of …

Acquired hemophilia A (AHA) is a severe auto‐immune bleeding disorder. Treatment of AHA
is burdensome and optimal management is still unresolved. Therefore a retrospective …

Acquired hemophilia A (AH) is an autoimmune disease that leads to potentially severe
bleeding. Management relies on rapid and accurate diagnosis, control of bleeding episodes …

Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors)
against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and …

Focuses on clinical features, laboratory diagnosis, prognostic factors and therapeutic
management of patients with acquired hemophilia. Association of acquired hemophilia with …

The inhibition of factor VIII by autoantibody development, or acquired hemophilia, occurs in
approximately one person per million each year and can cause life-threatening bleeding …

Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …

Acquired haemophilia A is an auto‐immune disease caused by an inhibitory antibody to
factor VIII. Patients with an acquired factor VIII inhibitor are at risk of life‐and limb …

Although extremely rare, acquired haemophilia A (AHA) can cause severe bleeding, which
may be fatal. The underlying causes of autoantibody development are not fully understood …